about
Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future ProspectivesTLR4 drives the pathogenesis of acquired cholesteatoma by promoting local inflammation and bone destruction.Large-scale proteomics differentiates cholesteatoma from surrounding tissues and identifies novel proteins related to the pathogenesis.Cholesteatoma fibroblasts promote epithelial cell proliferation through overexpression of epiregulin.Middle ear cholesteatoma in 11 dogs.Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesis.Galectin-1, -3, -7 expressions in congenital and acquired pediatric cholesteatomas compared to external auditory canal skin.Cholesteatoma-associated fibroblasts modulate epithelial growth and differentiation through KGF/FGF7 secretion.Ossicular chain lesions in cholesteatoma.Optical imaging with a high-resolution microendoscope to identify cholesteatoma of the middle earSerum myeloperoxidase activity, total antioxidant capacity and nitric oxide levels in patients with chronic otitis mediaAggressiveness of pediatric cholesteatoma. Do we have an evidence?Evaluation of temporal bone cholesteatoma and the correlation between high resolution computed tomography and surgical finding.The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatomaManagement of otitis media-related diseases in children with a cochlear implant.Acquired cholesteatoma pathogenesis: stepwise explanations.Removal of frontal sinus keratoma solely via endoscopic sinus surgery.Acquired cholesteatoma: summary of the cascade of molecular events.Etiopathogenesis of acquired cholesteatoma: prominent theories and recent advances in biomolecular research.A new theory on the pathogenesis of acquired cholesteatoma: Mucosal traction.Bilateral otoneurological pathology: To operate or not?Cholesteatoma growth and proliferation: posttranscriptional regulation by microRNA-21.44-plex cytokine profile of cholesteatoma.NOD-Like Receptor Signaling in Cholesteatoma.Survival signaling and terminal differentiation in cholesteatoma epithelium.FleQ, a Transcriptional Activator, Is Required for Biofilm Formation In Vitro But Does Not Alter Virulence in a Cholesteatomas Model.Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity.Comparative analysis of the expression of involucrin, filaggrin and cytokeratin 4, 10, 16 in cholesteatoma.Congenital cholesteatoma tract presenting as a postaural swelling.EGFR expression in acquired middle ear cholesteatoma in children and adults.Identification of altered protein abundances in cholesteatoma matrix via mass spectrometry-based proteomic analysis.Updates and knowledge gaps in cholesteatoma research.Quantitative measurement of m-RNA levels to assess expression of cyclooxygenase-II, inducible nitric oxide synthase and 12-lipoxygenase genes in middle ear cholesteatoma.Expression of Ras-related C3 botulinum toxin substrate 1 (RAC1) in human cholesteatoma.Role of Langerhans cells, Ki-67 protein and apoptosis in acquired cholesteatoma: prospective clinical study.Expression of tumor necrosis factor-like weak inducer of apoptosis in human middle ear cholesteatoma.Expression of the epidermal growth factor system in human middle ear cholesteatoma.Oxidative stress in chronic otitis media.Expression of Prostaglandin E2 Receptors in Acquired Middle Ear Cholesteatoma.Autologous meatal skin graft implantation and intratympanic injection of Pseudomonas aeruginosa: a new experimental mouse model of acquired middle ear cholesteatoma.
P2860
Q28080194-C5E6AF85-8D6E-4057-941D-72D2B7BEF2C7Q30396344-F061FD4E-7293-49D5-A499-1B4117687D89Q34005025-E8284D45-5DE7-4694-93F1-7295CD8866CBQ34795889-5D39F755-3DC8-4E12-B837-276EC78271BCQ34983090-51A66D6E-A16E-4B40-8F35-96B9B88E181EQ35097737-8B51EE7A-2EA4-429D-8098-A51A04BDFD9FQ36049180-A6A2105D-FFF2-40DB-A3C9-7A19C9685A63Q36124848-F3F3F6E0-172E-4DFE-9872-C73C11BE5D81Q36537450-04D75EB3-9BD4-48D8-A044-371A2E689246Q36721531-7B70B870-03C2-4928-A9F1-25F7A6CC436BQ36964007-39A3B2AD-1CAF-4F52-AF68-FFB2B6BC5610Q36965360-365A8C6D-7FF1-418C-944B-6A263C31A42AQ37218994-5302C528-9465-4B51-9FC7-D1119C8678BDQ37339233-6E5BD172-B620-48FF-8D69-D555845F2472Q37365332-E855C0A0-93E7-462C-A3DF-F0E64CFEB784Q37692548-3D96CE49-5234-4193-BE86-6363D6109704Q37770136-0BA3FB58-A11C-436A-BDD1-5786137748AFQ38105208-20BB3C86-B1EF-4205-A161-5C738B278531Q38239857-D755B626-E813-4618-8FA2-5BF8950FBB8FQ38503456-6B11569D-8261-403C-BD83-B5FAA3292B27Q39144113-5A7A7E82-C5C8-44F6-95A6-7466AB46502EQ39273836-6877AF25-E9CF-4590-8858-C5AA5B75BE1EQ39311429-34BD6AF7-3DE2-4818-93BB-832189504098Q39682752-4EB3CD7F-5D48-4E23-80E5-D0FCCECC4CD0Q39794806-9B8F1375-870A-4890-88B7-F8BF381B9996Q40648854-24EA162D-FC1B-41DD-85B7-30F95DA61A3FQ41270995-D585A41F-4F01-49B9-81B0-5C73D3B3B888Q41844983-7E701CF2-4020-43C8-A026-404743CADB2FQ41963135-8DEB0EC3-9F0F-416D-8285-9C0CECEBD3DBQ42492298-1303946B-38A2-4C3E-8292-DAA7B403A572Q43154464-4BED1C0A-8040-461A-82FA-50DC25D8859AQ43211811-E350AB02-D067-478E-910E-2D745F4312ABQ43802965-43449944-C55E-40FD-B58E-86DDD45BDA2CQ44061872-56488644-0BFD-4368-8A50-29BF51214907Q44279529-C4943AAE-EEFB-499B-A2B2-4ED264D17D0AQ44762306-9BF68B1C-BE52-4ED7-A6F1-363FDBA47662Q45296367-AD023511-D0D7-4861-AA87-6D77DC4AEE2CQ46566663-DCB9F5B2-1A76-46DD-A102-301A2EEE132AQ47909992-F1A36A6A-6502-48EA-81DF-E46BD6F0C5F2Q49039414-0E4A27A3-E357-437A-B4C6-C6958DA22870
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Etiopathogenesis of cholesteatoma.
@ast
Etiopathogenesis of cholesteatoma.
@en
Etiopathogenesis of cholesteatoma.
@nl
type
label
Etiopathogenesis of cholesteatoma.
@ast
Etiopathogenesis of cholesteatoma.
@en
Etiopathogenesis of cholesteatoma.
@nl
prefLabel
Etiopathogenesis of cholesteatoma.
@ast
Etiopathogenesis of cholesteatoma.
@en
Etiopathogenesis of cholesteatoma.
@nl
P2093
P1476
Etiopathogenesis of cholesteatoma
@en
P2093
Henning Hildmann
Holger Sudhoff
Jörg Ebmeyer
Mathias Wagner
Stefan Dazert
P2888
P356
10.1007/S00405-003-0623-X
P577
2003-06-27T00:00:00Z
P5875
P6179
1041399720